(Pyridin-4-yl)boronic acid → 8-Fluoro-6-pyridin-4-yl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one
Reaction equation
Br[C:2]1[C:10]2[N:9]3[CH2:11][CH2:12][NH:13][C:14](=[O:15])[C:8]3=[CH:7][C:6]=2[CH:5]=[C:4]([F:16])[CH:3]=1.[N:17]1[CH:22]=[CH:21][C:20](B(O)O)=[CH:19][CH:18]=1>>[F:16][C:4]1[CH:3]=[C:2]([C:20]2[CH:21]=[CH:22][N:17]=[CH:18][CH:19]=2)[C:10]2[N:9]3[CH2:11][CH2:12][NH:13][C:14](=[O:15])[C:8]3=[CH:7][C:6]=2[CH:5]=1Participants
3
Procedure
The title compound, white solid (44 mg, 63%), MS (ISP) m/z=282.3 [(M+H)+], mp 323.5° C., was prepared in accordance with the general method of example 1 from 6-bromo-8-fluoro-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one (intermediate 1) (70.8 mg, 0.25 mmol) and commercially available pyridine-4-ylboronic acid (39.9 mg, 0.325 mmol).
Sources & evidence
- ORD record
- ord-3ec1c0b44c3a4e4f851554c2ea325977
- Source dataset
- uspto-grants-2016_03
- Patent number
- US09284321B2
Reaction notes
Loading…